Legend Biotech (LEGN) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Legend Biotech (NASDAQ: LEGN) recently:

• 10/19/2026 – Legend Biotech was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/13/2026 – Legend Biotech had its price target lowered by Barclays PLC from $74.00 to $68.00. They now have an “overweight” rating on the stock.
• 10/9/2026 – Legend Biotech had its price target lowered by JPMorgan Chase & Co. from $35.00 to $33.00. They now have a “neutral” rating on the stock.
• 10/8/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $58.00 to $56.00. They now have an “outperform” rating on the stock.
• 10/2/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/28/2026 – Legend Biotech had its “buy” rating reaffirmed by UBS Group AG. They now have a $65.00 price target on the stock.
• 9/28/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 9/16/2026 – Legend Biotech was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/11/2026 – Legend Biotech had its price target lowered by Barclays PLC from $78.00 to $74.00. They now have an “overweight” rating on the stock.
• 9/4/2026 – Legend Biotech was given a new $65.00 price target by Morgan Stanley.
• 9/4/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 9/1/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insiders Place Their Bets

In other news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the company’s stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total transaction of $258,920.20. Following the transaction, the director owned 52,731 shares in the company, valued at approximately $498,835.26. This represents a 34.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Carlos E. Santos sold 5,430 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $9.14, for a total transaction of $49,630.20. Following the transaction, the chief financial officer owned 14,246 shares in the company, valued at $130,208.44. This represents a 27.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.02% of the company’s stock.

Legend Biotech Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. The company’s primary technology is chimeric antigen receptor T-cell (CAR-T) therapy, which genetically modifies a patient’s immune cells to recognize and attack cancer cells.

Legend Biotech’s leading product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma.